CV Sciences Q3 revenue falls

CV Sciences

13/11/2025 21:09

Overview

CV Sciences Q3 2025 revenue declines 16% yr/yr due to out-of-stock issues and restrictive regulations

Company reports adjusted EBITDA loss of $118,000 for Q3 2025, widening from prior year

CV Sciences launched Ignite, a men's performance formula, expanding +PlusCBD™ product line

Outlook

Company focuses on organic growth and strategic M&A to enhance revenue

Restrictive hemp legislation delayed for one year, allowing industry input

Result Drivers

OUT-OF-STOCK ISSUES - Revenue decline attributed to out-of-stock issues for key products

NEW PRODUCT CONTRIBUTION - 39% of Q3 revenue from products launched since January 2023

REGULATORY IMPACT - Restrictive regulations in certain states impacted sales volume

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
$3.26 mln
Q3 Net Income
-$382,000
Q3 Gross Profit
$1.58 mln
Q3 Operating Expenses
$1.85 mln
Q3 Operating Income
-$275,000
Q3 Pretax Profit
-$382,000


Press Release: ID:nACSVhgtXa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)